Pieris Pharmaceuticals (PIRS) Insider Trading & Ownership $15.87 -0.08 (-0.50%) (As of 11/15/2024 ET) Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Pieris Pharmaceuticals (NASDAQ:PIRS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage6.39%Number OfInsiders Buying(Last 12 Months)3Amount OfInsider Buying(Last 12 Months)$92,311.00Number OfInsiders Selling(Last 12 Months)0 Get PIRS Insider Trade Alerts Want to know when executives and insiders are buying or selling Pieris Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address PIRS Insider Buying and Selling by Quarter Ad Golden CrestTrump Can’t Stop This Crisis—Your Savings Are in JeopardyA lot of people are betting on Trump's re-election to solve everything. They think that if he wins, the economy will bounce back, and their retirement will be safe. But here's the cold, hard truth: It's too late for that.Click Here For Your Free Guide Pieris Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails8/12/2024Adar1 Capital Management, LlcMajor ShareholderBuy3,000$15.88$47,640.00 8/9/2024Adar1 Capital Management, LlcMajor ShareholderBuy3,000$14.89$44,670.00 8/7/2024James A GeraghtyDirectorBuy1$1.00$1.00 (Data available from 1/1/2013 forward) PIRS Insider Trading Activity - Frequently Asked Questions Who is on Pieris Pharmaceuticals's Insider Roster? The list of insiders at Pieris Pharmaceuticals includes Adar1 Capital Management, Llc, Christopher P Kiritsy, James A Geraghty, and Tim Demuth. Learn more on insiders at PIRS. What percentage of Pieris Pharmaceuticals stock is owned by insiders? 6.39% of Pieris Pharmaceuticals stock is owned by insiders. Learn more on PIRS's insider holdings. Which Pieris Pharmaceuticals insiders have been buying company stock? The following insiders have purchased PIRS shares in the last 24 months: Adar1 Capital Management, Llc ($92,310.00), Christopher P Kiritsy ($8,500.00), and James A Geraghty ($1.00). How much insider buying is happening at Pieris Pharmaceuticals? Insiders have purchased a total of 6,126 PIRS shares in the last 24 months for a total of $100,811.00 bought. Pieris Pharmaceuticals Key ExecutivesMr. Stephen S. Yoder J.D. (Age 48)CEO, President & Director Compensation: $744.13kMr. Thomas Bures (Age 49)Senior VP, CFO & Treasurer Compensation: $487.5kDr. Shane Olwill Ph.D. (Age 48)Senior VP & Chief Development Officer Compensation: $463.91kMaria KelmanExecutive Director of Investor RelationsMr. Prompong Chaikul (Age 37)Chief Supply Chain Officer Dr. Florian Witte Ph.D.VP and Head of Alliance Management & Early Project Leadership More Insider Trading Tools from MarketBeat Related Companies FibroGen Insider Selling Clearside Biomedical Insider Selling CytomX Therapeutics Insider Selling Vistagen Therapeutics Insider Selling Ikena Oncology Insider Selling CASI Pharmaceuticals Insider Selling Cue Biopharma Insider Selling Aileron Therapeutics Insider Selling Assertio Insider Selling Metagenomi Insider Selling Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles Insiders Bet Big on These Small Cap StocksHere’s Why Etsy Management Is Investing $1 Billion in BuybacksInsider Buying Signals Upside for These 3 StocksBig Buybacks Announced: 3 Stocks Insiders Are Banking OnInsiders Are Buying High-Yielding Delek Logistics Partners This page (NASDAQ:PIRS) was last updated on 11/16/2024 by MarketBeat.com Staff From Our PartnersBuffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of...Golden Crest | SponsoredCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – ...True Gold Republic | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this BEFORE November 19th.Brownstone Research | Sponsored🗓️ My First LIVE Event in 5 Years!Give us 60 minutes and we’ll show you how we’ve compressed 15 years of stock market gains into one day.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pieris Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pieris Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.